Results 21 to 30 of about 725,921 (266)

Clinical efficacy and safety of linagliptin in patients with diabetes type 2

Медицинский совет, 2016
Treatment of diabetes mellitus type 2 (T2DM) is a serious challenge which forces to search for new approaches in order to improve the results of pharmacotherapy. Recent advances in diabetology pertain to incretin-directed therapies.
E. V. Biryukova, A. M. Mkrtumyan
doaj   +1 more source

Dysregulation of Insulin-Linked Metabolic Pathways in Alzheimer’s Disease: Co-Factor Role of Apolipoprotein E 4

Journal of Alzheimer's Disease Reports, 2020
Background: Brain insulin resistance and deficiency are well-recognized abnormalities in Alzheimer’s disease (AD) and likely mediators of impaired energy metabolism.
James Robbins, Oriol Busquets, Ming Tong, Suzanne M. de la Monte   +3 more
doaj   +1 more source

Gastric inhibitory polypeptide receptor methylation in newly diagnosed, drug-naïve patients with type 2 diabetes: a case-control study. [PDF]

PLoS ONE, 2013
GIP action in type 2 diabetic (T2D) patients is altered. We hypothesized that methylation changes could be present in GIP receptor of T2D patients.
Silvia Canivell, Elena G Ruano, Antoni Sisó-Almirall, Belchin Kostov, Luis González-de Paz, Eduardo Fernandez-Rebollo, Felicia Hanzu, Marcelina Párrizas, Anna Novials, Ramon Gomis   +9 more
doaj   +1 more source

Gastric inhibitory polypeptide receptor: association analyses for obesity of several polymorphisms in large study groups

BMC Medical Genetics, 2009
Background Gastric inhibitory polypeptide (GIP) is postulated to be involved in type 2 diabetes mellitus and obesity. It exerts its function through its receptor, GIPR.
Rief Winfried, Reinehr Thomas, Völzke Henry, Rosskopf Dieter, Bornhorst Alexa, Grallert Harald, Wang Hai-Jun, Nguyen Thuy T, Brönner Günter, Scherag André, Vogel Carla IG, Illig Thomas, Wichmann H-Erich, Schäfer Helmut, Hebebrand Johannes, Hinney Anke   +15 more
doaj   +1 more source

Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management

Journal of Obesity & Metabolic Syndrome, 2023
The combination of glucagon-like peptide-1 (GLP-1) with other gut hormones including the glucose-dependent insulinotropic polypeptide (GIP) has been explored to complement and enhance further the GLP-1 effects on glycemia and weight loss.
Rachel Sinha, Dimitris Papamargaritis, Jack A. Sargeant, Melanie J. Davies   +3 more
doaj   +1 more source

Factors Related to Blood Intact Incretin Levels in Patients with Type 2 Diabetes Mellitus [PDF]

Diabetes & Metabolism Journal, 2019
BackgroundWe performed this study to identify factors related to intact incretin levels in patients with type 2 diabetes mellitus (T2DM).MethodsWe cross-sectionally analyzed 336 patients with T2DM.
Soyeon Yoo, Eun-Jin Yang, Gwanpyo Koh
doaj   +1 more source

A Standardized Pathology Report for Gastric Cancer: 2nd Edition [PDF]

, 2023
The first edition of ‘A Standardized Pathology Report for Gastric Cancer’ was initiated by the Gastrointestinal Pathology Study Group of the Korean Society of Pathologists and published 17 years ago. Since then, significant advances have been made in the
김현기, 최윤정
core   +1 more source

Incretins today: multiple effects and therapeutic potential

Сахарный диабет, 2019
Glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) are the incretin hormones initially discovered in the 1960s. GIP and GLP-1 have gained great scientific interest due to their properties in increasing insulin secretion ...
Oksana V. Tsygankova, Varvara V. Veretyuk, Alexander S. Ametov   +2 more
doaj   +1 more source

Reagents and models for detecting endogenous GLP1R and GIPR

EBioMedicine, 2021
Glucagon-like peptide-1 receptor (GLP1R) agonists target the GLP1R, whereas dual GLP1R/ gastric inhibitory polypeptide receptor (GIPR) agonists target both the GLP1R and GIPR. Despite the importance of these drug classes for the treatment of diabetes and
Julia Ast, Johannes Broichhagen, David J. Hodson   +2 more
doaj   +1 more source

Detection of glycated gastric inhibitory polypeptide within the intestines of diabetic obese (ob/ob) mice

, 2001
Gastric inhibitory polypeptide (GIP) is produced within endocrine cells of the small intestine and released into the circulation upon nutrient ingestion.
Abdel-Wahab, Y.H.A., Flatt, P.R., Mooney, Mark; id_orcid, Morgan, L.M., O'Harte, F.P.M.   +4 more
core   +3 more sources